14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 20 May 2024

Trading levels for VKTX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 72.67 8.46 %
R2 70.98 5.94 %
R1 69.94 4.39 %
Current price: 67.00
Support S1 66.57 -0.639 %
S2 65.53 -2.19 %
S3 63.85 -4.71 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 80.83 20.64 %
R2 77.05 15.00 %
R1 74.00 10.45 %
Current price 67.00
Support S1 65.05 -2.91%
S2 63.44 -5.31%
S3 62.56 -6.63%

VKTX Predictions History

5 years ago
PumpTheseNumbers predicted that VKTX for 2019-03-04 is going $8.50 (-2.30%)

5 years ago
PumpTheseNumbers predicted that VKTX for 2019-02-26 is going $8.55 (0.71%)

5 years ago
JS predicted that VKTX for 2019-02-26 is going $8.73 (2.83%)

5 years ago
JS predicted that VKTX for 2019-02-26 is going $8.73 (2.83%)

5 years ago
Gp predicted that VKTX for 2019-02-26 is going $8.67 (2.12%)

5 years ago
Cody.Long.98847 predicted that VKTX for 2019-01-29 is going $6.35 (-23.12%)

Rank:

5 years ago
JS predicted that VKTX for 2018-09-20 is going $19.71 (3.90%)

5 years ago
anand15 predicted that VKTX for 2018-09-20 is going $13.00 (-33.84%)

Rank:

5 years ago
JS predicted that VKTX for 2018-07-25 is going $10.66 (-5.16%)

5 years ago
paoooolo predicted that VKTX for 2018-07-25 is going $11.50 (7.78%)

Rank:
Click to get the best stock tips daily for free!

About Viking Therapeutics

Viking Therapeutics Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also dev... VKTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT